AERI - Aerie Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
42.87
+0.14 (+0.33%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close42.73
Open42.30
Bid33.15 x 800
Ask43.19 x 800
Day's Range41.07 - 43.41
52 Week Range40.50 - 74.75
Volume519,274
Avg. Volume540,839
Market Cap1.949B
Beta (3Y Monthly)0.51
PE Ratio (TTM)N/A
EPS (TTM)-4.96
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est83.10
Trade prices are not sourced from all markets
  • Aerie Pharmaceuticals (AERI): Moving Average Crossover Alert
    Zacks5 days ago

    Aerie Pharmaceuticals (AERI): Moving Average Crossover Alert

    Aerie Pharmaceuticals, Inc. (AERI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

  • See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
    Markit9 days ago

    See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

    Aerie Pharmaceuticals Inc NASDAQ NMS:AERI

  • Aerie (AERI) Q3 Earnings Miss, Rhopressa Gains Traction
    Zacks10 days ago

    Aerie (AERI) Q3 Earnings Miss, Rhopressa Gains Traction

    Aerie's (AERI) Q3 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.

  • Business Wire11 days ago

    Aerie Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Stifel 2018 Healthcare Conference on Tuesday, November 13, 2018 at 10:15 a.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.

  • Thomson Reuters StreetEvents11 days ago

    Edited Transcript of AERI earnings conference call or presentation 6-Nov-18 10:00pm GMT

    Q3 2018 Aerie Pharmaceuticals Inc Earnings Call

  • Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates
    Zacks11 days ago

    Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates

    Aerie (AERI) delivered earnings and revenue surprises of -30.08% and 29.79%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press12 days ago

    Aerie: 3Q Earnings Snapshot

    The North Carolina, North Carolina-based company said it had a loss of $1.96 per share. Losses, adjusted for non-recurring costs, were $1.73 per share. The results did not meet Wall Street expectations. ...

  • Business Wire12 days ago

    Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

    Conference Call and Webcast Today, November 6th, at 5:00 p.m. ET

  • Business Wire19 days ago

    Aerie Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018

    Aerie Pharmaceuticals, Inc. (AERI) (Aerie or the Company), announced today that its third quarter 2018 financial results will be released after the market closes on Tuesday, November 6, 2018. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update. The live webcast and a replay may be accessed by visiting the Company's website at http://investors.aeriepharma.com.

  • GlobeNewswire24 days ago

    Report: Exploring Fundamental Drivers Behind Invitae, Aerie Pharmaceuticals, Gevo, Global Medical REIT, Cyclacel Pharmaceuticals, and Toll Brothers — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Oct. 25, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Aerie completes Durham HQ expansion
    American City Business Journals25 days ago

    Aerie completes Durham HQ expansion

    Aerie Pharmaceuticals is bolstering its Triangle-area infrastructure in a move to prepare it for more clinical testing and on-site production.

  • Business Wire26 days ago

    Aerie Pharmaceuticals Establishes GMP PRINT® Production Facility in an Expanded Global Headquarters

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that it has built and commenced operation of its GMP (Good Manufacturing Practices)-validated manufacturing facility for production of ophthalmic implants using the proprietary PRINT® (Particle Replication in Non-wetting Templates) Technology platform. As a result of the compact footprint and efficiency of the PRINT® manufacturing process, the custom-designed 1,000 sq. ft. laboratory provides adequate capacity to produce all of the clinical product supply necessary for Aerie’s two lead development programs focused on retinal diseases.

  • Simply Wall St.last month

    Is There An Opportunity With Aerie Pharmaceuticals Inc’s (NASDAQ:AERI) 48% Undervaluation?

    How far off is Aerie Pharmaceuticals Inc (NASDAQ:AERI) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is Read More...

  • See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

    Short interest is moderate for AERI with between 5 and 10% of shares outstanding currently on loan. The net inflows of $4.08 billion over the last one-month into ETFs that hold AERI are not among the highest of the last year and have been slowing.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: GW Pharmaceuticals and Aerie Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / October 15, 2018 / U.S. markets bounced on Friday, erasing some of the losses for the week, as the third quarter earnings season kicked off. The Dow Jones Industrial Average ...

  • Business Wirelast month

    Aerie Pharmaceuticals, Inc. Announces Drug Application for Regulatory Approval Accepted for Review in Europe

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today reported that the EMA has accepted for review the MAA for Rhokiinsa® (netarsudil ophthalmic solution) 0.02%. Rhokiinsa® is currently marketed as Rhopressa® in the United States and is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

  • Business Wire2 months ago

    Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

    Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that Richard Rubino, Chief Financial Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Tuesday, ...

  • Business Wire2 months ago

    Aerie Pharmaceuticals Announces Appointment of Damien Monaghan, Quality Director

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the appointment of Damien Monaghan, Quality Director, reporting to Finbar O’Neill, EU Director, Quality & Regulatory Compliance. Mr. Monaghan will lead quality assurance and quality control operations for Aerie’s manufacturing plant in Athlone, Ireland. Mr. Monaghan most recently held a related position at Alkermes Pharma Ireland Limited.

  • See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.

    Short interest is moderate for AERI with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • Business Wire2 months ago

    Aerie Pharmaceuticals to Present at Ophthalmology Futures Forums in Vienna, Austria

    Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that Richard Rubino, Chief Financial Officer, will present at the Ophthalmology Futures European Forum held prior to the 36th Congress ...

  • Business Wire2 months ago

    Aerie Pharmaceuticals Appoints David W. Gryska to the Company’s Board of Directors

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that David W. Gryska has been appointed to the Company’s Board of Directors and will also be a member of the Audit Committee of the Board. Mr. Gryska recently announced his planned retirement at the end of 2018 as the Chief Financial Officer and Executive Vice President of Incyte Corp., and is currently on the boards of Seattle Genetics, Inc. and PDL BioPharma, Inc. Previously, he held the position of President, CEO, COO and Director at Myrexis, Inc., Chief Financial Officer and Senior Vice President at Celgene Corp., and Chief Financial Officer and Senior Vice President at Scios, Inc. Mr. Gryska has spent over 20 years as a senior executive at life science and biotechnology companies with extensive experience relating to financings, acquisitions, global expansion and strategic transactions.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Momenta Pharmaceuticals and Aerie Pharmaceuticals

    The Dow Jones Industrial Average climbed 0.44 percent to close at 25,971.06, while the S&P 500 Index increased 0.37 percent to close at 2,887.89. The Nasdaq Composite Index gained 0.61 percent to close at 7,972.47.

  • Business Wire2 months ago

    Aerie Pharmaceuticals Announces Appointment of Robert Finan as Director of Finance

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the appointment of Robert Finan, Director of Finance, reporting to Christopher Staten, Vice President of Finance. Mr. Finan will lead Aerie’s finance, operations and strategy activities for Aerie’s manufacturing plant in Athlone, Ireland. Mr. Finan most recently held a related position at Sanofi Genzyme Ireland.

  • Business Wire2 months ago

    Aerie Pharmaceuticals Announces Appointment of Thomas A. Shepard as Vice President, Implant Manufacturing

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the appointment of Thomas A. Shepard as Vice President, Implant Manufacturing, reporting to Casey Kopczynski, Ph.D., Aerie’s Chief Scientific Officer. Mr. Shepard will lead Aerie’s implant manufacturing facility in Durham, North Carolina, including responsibility for the development, manufacture and global supply of Aerie’s ophthalmic drug-eluting implants. Mr. Shepard most recently held a related position at Pfizer, Inc.

  • Why Is Aerie (AERI) Down 10.6% Since Last Earnings Report?
    Zacks2 months ago

    Why Is Aerie (AERI) Down 10.6% Since Last Earnings Report?

    Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.